The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Human Drug-Metabolizing Enzyme Polymorphisms: Effects on Risk of Toxicity and Cancer
Abstract
A growing number of human genetic polymorphisms in drug-metabolizing enzymes (DMEs) are being characterized. Some of these have been shown, quite convincingly, to be correlated with risk of toxicity or cancer, whereas others presently remain equivocal. There is good evidence that the correlation is stronger in populations exposed to a variety of environmental procarcinogens; perhaps 30% of DME substrates are able to be metabolically potentiated. Phase I DMEs, most of which represent cytochromes P450, metabolically activate procarcinogens to genotoxic electrophilic intermediates, and Phase II DMEs conjugate the intermediates to water-soluble derivatives, completing the detoxification cycle. It follows that genetic differences in the regulation, expression and activity of genes coding for Phase I and Phase II DMEs would be crucial factors in defining cancer susceptibility and the toxic or carcinogenic power of environmental chemicals. Not all Phase I and Phase II DMEs are implicated in detoxification; previous work from this and from other laboratories has identified candidate Phase I and Phase II genes in which certain alleles are more likely to be associated with cancer susceptibility. In some cases, the allelic frequencies vary dramatically between ethnic groups. In this review, our current knowledge about polymorphisms in the following genes are updated: the aromatic hydrocarbon receptor (AHR), the CYP1A1 structural gene (which encodes aryl hydrocarbon hydroxylase activity), the CYP1A2 structural gene (arylamine oxidations), the CYP2C19 gene (S-mephenytoin 4'-hydroxylase), the CYP2D6 gene (debrisoquine hydroxylase), the CYP2E1 gene (N,N-dimethylnitrosamine N-demethylase), the null mutant for the GSTM1 gene (glutathione transferase mu), and the NAT2 gene (arylamine N-acetyltransferase). If unequivocal biomarkers of genetic susceptibility to cancer and toxicity can be developed successfully, then identification of individuals at increased risk would be very helpful in the fields of public health and preventive medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poland, A., & Knutson, J. C. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.002505 · Cited by 2,515
Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
Guengerich, F. P., Kim, D. H., & Iwasaki, M. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00020a008 · Cited by 1,169
Immune System Impairment and Hepatic Fibrosis in Mice Lacking the Dioxin-Binding Ah Receptor
Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S. T., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., & Gonzalez, F. J. (1995) · Science · doi:10.1126/science.7732381 · Cited by 1,075
Self-citationCloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor.
Burbach, K. M., Poland, A., & Bradfield, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.17.8185 · Cited by 831
Nomenclature for human glutathione transferases
Mannervik, B., Awasthi, Y. C., Board, P. G., Hayes, J. D., Di Ilio, C., Ketterer, B., Listowsky, I., Morgenstern, R., Muramatsu, M., Pearson, W. R., et al. (1992) · Biochemical Journal · doi:10.1042/bj2820305 · Cited by 671
Hayashi, S.-I., Watanabe, J., & Kawajiri, K. (1991) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123619 · Cited by 666
N-acetylation pharmacogenetics.
Weber, W. W., & Hein, D. W. (1985) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06816-4 · Cited by 648
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Aryl Hydrocarbon Hydroxylase Inducibility and Bronchogenic Carcinoma
Kellermann, G., Shaw, C. R., & Luyten-Kellerman, M. (1973) · New England Journal of Medicine · doi:10.1056/nejm197311012891802 · Cited by 591
Biochemistry and molecular biology of the human CYP2C subfamily
Goldstein, J. A., & de Morais, S. M. F. (1994) · Pharmacogenetics · doi:10.1097/00008571-199412000-00001 · Cited by 529
Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N., & Watanabe, J. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)80721-t · Cited by 472
The Ah Locus: Genetic Differences in Toxicity, Cancer, Mutation, and Birth Defects
Nebert, D. W. (1989) · Critical Reviews in Toxicology · doi:10.3109/10408448909017908 · Cited by 453
Self-citationGenetic and Molecular Aspects of 2,3,7,8-Tetra-Chlorodibenzo-P-Dioxin Action
Whitlock, J. P. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.001343 · Cited by 446
BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435
The AH-receptor: genetics, structure and function
Swanson, H. I., & Bradfield, C. A. (1993) · Pharmacogenetics · doi:10.1097/00008571-199310000-00001 · Cited by 434
NEBERT, D. W., PUGA, A., & VASILIOU, V. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35928.x · Cited by 423
Self-citationButler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Nomenclature for N-acetyltransferases
Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J., Evans, D. A. P., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U., Relling, M. V., et al. (1995) · Pharmacogenetics · doi:10.1097/00008571-199502000-00001 · Cited by 412
cDNA cloning and structure of mouse putative Ah receptor
Ema, M., Sogawa, K., Watanabe, N., Chujoh, Y., Matsushita, N., Gotoh, O., Funae, Y., & Fujii-Kuriyama, Y. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91185-s · Cited by 403
Cloning and expression of a human Ah receptor cDNA.
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., & Bradfield, C. A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13282-3 · Cited by 348
Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors.
Ema, M., Ohe, N., Suzuki, M., Mimura, J., Sogawa, K., Ikawa, S., & Fujii-Kuriyama, Y. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46990-6 · Cited by 329
The Ah receptor and the mechanism of dioxin toxicity
Landers, J. P., & Bunce, N. J. (1991) · Biochemical Journal · doi:10.1042/bj2760273 · Cited by 323
Analysis of the four alleles of the murine aryl hydrocarbon receptor
Poland, A., Palen, D., & Glover, E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09833-5 · Cited by 303
Kouri, R. E., McKinney, C. E., Slomiany, D. J., Snodgrass, D. R., Wray, N. P., & McLemore, T. L. (1982) · PubMed · Cited by 260
Crespi, C. L., Penman, B. W., Gelboin, H. V., & Gonzalez, F. J. (1991) · Carcinogenesis · doi:10.1093/carcin/12.7.1197 · Cited by 235
Shimada, T., Yun, C. H., Yamazaki, H., Gautier, J. C., Beaune, P. H., & Guengerich, F. P. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09132-1 · Cited by 235
Role of genetics and drug metabolism in human cancer risk
Nebert, D. W. (1991) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/0027-5107(91)90022-g · Cited by 231
Self-citationGlutathione conjugate mediated toxicities*1
Monks, T. J. (1990) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(90)90100-9 · Cited by 228
Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R., & Watanabe, M. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01838.x · Cited by 218
Persson, I., Johansson, I., Bergung, H., Dahl, M.-L., Seidegård, J., Rylander, R., Rannug, A., Högberg, J., & Sundberg, M. I. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80547-8 · Cited by 189
Pharmacogenetic Phenotyping and Genotyping: Present Status and Future Potential
Gonzalez, F. J., & Idle, J. R. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426010-00005 · Cited by 187
Nakajima, T., Elovaara, E., Anttila, S., Hirvonen, A., Camus, A.-M., Hayes, J. D., Ketterer, B., & Vainio, H. (1995) · Carcinogenesis · doi:10.1093/carcin/16.4.707 · Cited by 183
Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP.
Petersen, D. D., McKinney, C. E., Ikeya, K., Smith, H. H., Bale, A. E., McBride, O. W., & Nebert, D. W. (1991) · Europe PMC (PubMed Central) · Cited by 178
Self-citationN-acetyltransferase polymorphism
Hickman, D., & Sim, E. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90282-a · Cited by 177
Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W., & Kimura, S. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-9-1399 · Cited by 174
Self-citationPolymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance
Idle, J. R., & Smith, R. L. (1979) · Drug Metabolism Reviews · doi:10.3109/03602537908993896 · Cited by 164
Fritz, G., Tano, K., MITRA, S. P., & Kaina, B. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.9.4660-4668.1991 · Cited by 160
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.
Liang, H. C., Li, H., McKinnon, R. A., Duffy, J. J., Potter, S. S., Puga, A., & Nebert, D. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1671 · Cited by 159
Self-citationDiverse point mutations in the human gene for polymorphic N-acetyltransferase.
Vatsis, K. P., Martell, K. J., & Weber, W. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6333 · Cited by 152
N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers
Hayes, R. B., Bi, W., Rothman, N., Broly, F., Caporaso, N. E., Feng, P., You, X., Yin, S., Woosley, R. L., & Meyer, U. (1993) · Carcinogenesis · doi:10.1093/carcin/14.4.675 · Cited by 131
Nebert, D. W., Petersen, D. D., & Puga, A. (1991) · Pharmacogenetics · doi:10.1097/00008571-199111000-00003 · Cited by 111
Self-citationNeonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2.
Pineau, T., Fernández‐Salguero, P. M., Lee, S. S. T., McPhail, T., Ward, J. M., & Gonzalez, F. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5134 · Cited by 108
Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Daly, A. K., Cholerton, S., Armstrong, M., & Idle, J. R. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s955 · Cited by 101
Is environmental carcinogenesis modulated by host polymorphism?
Idle, J. R. (1991) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(91)90021-f · Cited by 96
The murine Ah locus: a new allele and mapping to chromosome 12
Poland, A., Glover, E., & Taylor, B. A. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13026-5 · Cited by 79
ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY AND LARYNGEAL CARCINOMAS
Trell, E., Korsgaard, R., HOOD, B., Kitzing, P., Nordén, G., & Simonsson, B. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92859-2 · Cited by 77
Fryer, A. A., Zhao, L., Alldersea, J., Pearson, W. R., & Strange, R. C. (1993) · Biochemical Journal · doi:10.1042/bj2950313 · Cited by 75
Caffeine as a probe for CYP1A2 activity
Tang, B. K., Zhou, Y., Kadar, D., & KALOW, W. (1994) · Pharmacogenetics · doi:10.1097/00008571-199406000-00002 · Cited by 75
[58] Induction, purification, and characterization of cytochrome P450IIE
Yang, C. S., Patten, C., Ishizaki, H., et al. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)06129-q · Cited by 45
Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene
Fujii‐Kuriyama, Y., Ema, M., Mimura, J., et al. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512001-00018 · Cited by 44
Roberts, E. A., Golas, C. L., & Okey, A. B. (1986) · PubMed · Cited by 43
Research on the Aryl Hydrocarbon (Dioxin) Receptor Is Primed to Take Off
Hankinson, O. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1001 · Cited by 42
Wedlund, P. J., Kimura, S., Gonzalez, F. J., & Nebert, D. W. (1994) · PubMed · Cited by 31
Self-citationAryl hydrocarbon hydroxylase and 16?-hydroxylase in cultured human lymphocytes
Coomes, M. L., Mason, W. A., Muijsson, I. E., Cantrell, E. T., Anderson, D. E., & Busbee, D. L. (1976) · Biochemical Genetics · doi:10.1007/bf00485845 · Cited by 25
Cobb, R. R., Stoming, T. A., & Whitney, J. B. I. (1987) · Biochemical Genetics · doi:10.1007/bf00554549 · Cited by 23
Yokoi, T., Sawada, M., & Kamataki, T. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512001-00003 · Cited by 17
Human Ah receptor cDNA: analysis for highly conserved sequences
Itoh, S., & Kamataki, T. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.15.3578 · Cited by 16
Cited by
Nebert, D. W., Dalton, T. P., Okey, A. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400004200 · Cited by 1,182
Self-citationNebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., & Dalton, T. P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00310-x · Cited by 1,004
Self-citationNebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Self-citationGood genes, oxidative stress and condition–dependent sexual signals
Schantz, T. V., Bensch, S., Grahn, M., Hasselquist, D., & Wittzell, H. (1999) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.1999.0597 · Cited by 886
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Metadata
- Authors
- NEBERT, D. W., MCKINNON, R. A., & PUGA, A.
- Venue
- DNA and Cell Biology
- Publisher
- SAGE Publications
- Published
- 1996-04
- Volume
- 15
- Issue
- 4
- Pages
- 273-280
- ISSN
- 1044-5498 (ISSN-L)
- 1557-7430
- OpenAlex
- W2026550655
- Cited by
- 335
- References
- 58
- FWCI
- 21.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.